Voyager Therapeutics Inc (VYGR) — Cash Flow Quality Index

Latest as of December 2023: -0.42x

Voyager Therapeutics Inc (VYGR) has a Cash Flow Quality Index of -0.42x as of December 2023. Operating cash flow of $-23.76 Million is below net income of $56.40 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore VYGR cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.42x
Operating CF / Net Income

Operating Cash Flow

$-23.76 Million
USD

Net Income

$56.40 Million
USD

Data as of

Dec 2023
Most recent filing

Voyager Therapeutics Inc Cash Flow Quality Index (2020–2023)

Historical Cash Flow Quality Index for Voyager Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check VYGR cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Voyager Therapeutics Inc (2020–2023)

Year-by-year earnings quality comparison for Voyager Therapeutics Inc. For live market cap and the full company financial profile, see Voyager Therapeutics Inc market cap and net worth.

Year Quality Index Operating CF (USD) Net Income YoY Change
2023 0.59x $77.92 Million $132.33 Million ▲ +122.4%
2020 -2.63x $-96.72 Million $36.74 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.